We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the latest salvo in the federal crackdown on fraud among Florida compounders, a federal jury convicted pharmacist Stephen Chalker of participating in a $5 million scheme to defraud Medicare, Medicaid and TRICARE. Read More
A California federal judge dismissed a shareholder suit against Impax Laboratories alleging price-fixing but left the door open for an amended complaint. Read More
The FDA issued guidance Monday on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes. Read More
FDA Commissioner Scott Gottlieb announced a revised agreement Friday between the agency and states on interstate distribution of compounded drugs, responding to concerns that the existing distribution limits are too low. Read More
More than a year after shutting down its CAR-T trial after subjects died, Juno Therapeutics agreed to pay $24 million to investors who claimed they were not properly informed. Read More
Three national foundations have committed $30 million to the launch of a not-for-profit generic drug company — first announced in January — citing the rising prices of generics and the risks patients face from drug shortages. Read More
Maryland’s Attorney General filed charges against Insys Therapeutics over alleged violations of the state’s Consumer Protection Act, saying the company joined local health care providers in an “unfair and deceptive scheme” to promote its breakthrough pain drug Subsys. Read More